Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated T-cell engagers for cancer immunotherapy. Its TRACTr and related platforms aim to direct immune cells against solid tumors and other cancers while limiting systemic toxicity outside the tumor microenvironment. The pipeline is early-stage and research-driven, with limited product revenue typical of pre-commercial biotech.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -23.5 | — |
| Q2 2025 | 0 | — | -33.9 | — |
| Q3 2025 | 10 | — | -24.3 | — |
| Q4 2025 | 0 | — | -31.9 | — |
| Q1 2026 | 3.7 | — | -24.4 | — |
| Q2 2026 | 10.3 | — | -22 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: QuinStreet, Inc. (QNST), Tripadvisor, Inc. (TRIP), Savara Inc. (SVRA), Inventiva S.A. (IVA), IRADIMED CORPORATION (IRMD), OPKO Health, Inc. (OPK)